Effect of F Peptide on CCR5 Expression on Monocytes
| Preincubation (37°C for 60 min) . | Antibody . | Percentage of Stained Cells . | ||
|---|---|---|---|---|
| Medium . | Staurosporine* . | Calphostin C* . | ||
| Medium | (−) | 1.8% | 2.4% | 2.9% |
| Medium | Anti-CCR5 | 76.3% | 74.2% | 71.0% |
| F peptide | Anti-CCR5 | 30.2% | 69.9% | 52.8% |
| MIP-1β | Anti-CCR5 | 17.1% | 21.5% | 12.4% |
| Medium | Mouse IgG | 6.7% | 4.3% | 8.9% |
| Preincubation (37°C for 60 min) . | Antibody . | Percentage of Stained Cells . | ||
|---|---|---|---|---|
| Medium . | Staurosporine* . | Calphostin C* . | ||
| Medium | (−) | 1.8% | 2.4% | 2.9% |
| Medium | Anti-CCR5 | 76.3% | 74.2% | 71.0% |
| F peptide | Anti-CCR5 | 30.2% | 69.9% | 52.8% |
| MIP-1β | Anti-CCR5 | 17.1% | 21.5% | 12.4% |
| Medium | Mouse IgG | 6.7% | 4.3% | 8.9% |
Monocytes were preincubated with F peptide or MIP-1β for 60 minutes at 37°C followed by incubation with anti-CCR5 antibody or mouse IgG for 30 minutes at 4°C. The cells were then stained with FITC-conjugated antimouse IgG and subjected to FACS analyses.
Monocytes were preincubated with staurosporine or calphostin C before treatment with F peptide or MIP-1β.